Biogen Inc. (0R1B.L)
USD 119.28
(1.08%)
USD 119.28
(1.08%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.83 Billion USD | -3.32% |
| 2022 | 10.17 Billion USD | -7.36% |
| 2021 | 10.98 Billion USD | -18.32% |
| 2020 | 13.44 Billion USD | -6.49% |
| 2019 | 14.37 Billion USD | 6.88% |
| 2018 | 13.45 Billion USD | 9.61% |
| 2017 | 12.27 Billion USD | 7.21% |
| 2016 | 11.44 Billion USD | 6.36% |
| 2015 | 10.76 Billion USD | 10.93% |
| 2014 | 9.7 Billion USD | 39.97% |
| 2013 | 6.93 Billion USD | 25.66% |
| 2012 | 5.51 Billion USD | 9.27% |
| 2011 | 5.04 Billion USD | 7.04% |
| 2010 | 4.71 Billion USD | 7.75% |
| 2009 | 4.37 Billion USD | 6.83% |
| 2008 | 4.09 Billion USD | 29.19% |
| 2007 | 3.17 Billion USD | 69.41% |
| 2006 | 1.87 Billion USD | 9.25% |
| 2005 | 1.71 Billion USD | 7.38% |
| 2004 | 1.59 Billion USD | 134.96% |
| 2003 | 679.18 Million USD | -40.86% |
| 2002 | 1.14 Billion USD | 10.06% |
| 2001 | 1.04 Billion USD | 12.62% |
| 2000 | 926.45 Million USD | 16.62% |
| 1999 | 794.43 Million USD | 42.48% |
| 1998 | 557.58 Million USD | 28.46% |
| 1997 | 434.04 Million USD | 56.64% |
| 1996 | 277.09 Million USD | 82.67% |
| 1995 | 151.69 Million USD | -2.98% |
| 1994 | 156.34 Million USD | 14.62% |
| 1993 | 136.4 Million USD | 10.27% |
| 1992 | 123.7 Million USD | 101.47% |
| 1991 | 61.4 Million USD | 22.55% |
| 1990 | 50.1 Million USD | 75.79% |
| 1989 | 28.5 Million USD | 38.35% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.2 Billion USD | -7.79% |
| 2024 Q2 | 2.35 Billion USD | 6.94% |
| 2024 Q3 | 2.46 Billion USD | 4.79% |
| 2023 Q4 | 2.38 Billion USD | -5.69% |
| 2023 Q3 | 2.53 Billion USD | 3.03% |
| 2023 Q1 | 2.46 Billion USD | -3.18% |
| 2023 FY | 9.83 Billion USD | -3.32% |
| 2023 Q2 | 2.45 Billion USD | -0.28% |
| 2022 Q2 | 2.58 Billion USD | 2.26% |
| 2022 FY | 10.17 Billion USD | -7.36% |
| 2022 Q4 | 2.54 Billion USD | 1.42% |
| 2022 Q3 | 2.5 Billion USD | -3.11% |
| 2022 Q1 | 2.53 Billion USD | -7.39% |
| 2021 Q2 | 2.77 Billion USD | 3.01% |
| 2021 FY | 10.98 Billion USD | -18.32% |
| 2021 Q3 | 2.77 Billion USD | 0.14% |
| 2021 Q4 | 2.73 Billion USD | -1.62% |
| 2021 Q1 | 2.69 Billion USD | -5.56% |
| 2020 FY | 13.44 Billion USD | -6.49% |
| 2020 Q3 | 3.37 Billion USD | -8.3% |
| 2020 Q1 | 3.53 Billion USD | -3.73% |
| 2020 Q2 | 3.68 Billion USD | 4.17% |
| 2020 Q4 | 2.85 Billion USD | -15.51% |
| 2019 Q3 | 3.6 Billion USD | -0.46% |
| 2019 Q2 | 3.61 Billion USD | 3.64% |
| 2019 FY | 14.37 Billion USD | 6.88% |
| 2019 Q1 | 3.48 Billion USD | -1.04% |
| 2019 Q4 | 3.67 Billion USD | 1.98% |
| 2018 FY | 13.45 Billion USD | 9.61% |
| 2018 Q3 | 3.43 Billion USD | 2.46% |
| 2018 Q2 | 3.35 Billion USD | 7.2% |
| 2018 Q1 | 3.13 Billion USD | -5.32% |
| 2018 Q4 | 3.52 Billion USD | 2.54% |
| 2017 Q3 | 3.07 Billion USD | -0.02% |
| 2017 Q1 | 2.81 Billion USD | -2.13% |
| 2017 Q4 | 3.3 Billion USD | 7.45% |
| 2017 Q2 | 3.07 Billion USD | 9.52% |
| 2017 FY | 12.27 Billion USD | 7.21% |
| 2016 Q4 | 2.87 Billion USD | -2.84% |
| 2016 Q1 | 2.72 Billion USD | -3.96% |
| 2016 Q2 | 2.89 Billion USD | 6.14% |
| 2016 Q3 | 2.95 Billion USD | 2.13% |
| 2016 FY | 11.44 Billion USD | 6.36% |
| 2015 FY | 10.76 Billion USD | 10.93% |
| 2015 Q4 | 2.83 Billion USD | 2.21% |
| 2015 Q3 | 2.77 Billion USD | 7.19% |
| 2015 Q2 | 2.59 Billion USD | 1.44% |
| 2015 Q1 | 2.55 Billion USD | -3.25% |
| 2014 Q1 | 2.12 Billion USD | 8.34% |
| 2014 Q3 | 2.51 Billion USD | 3.72% |
| 2014 FY | 9.7 Billion USD | 39.97% |
| 2014 Q4 | 2.64 Billion USD | 5.15% |
| 2014 Q2 | 2.42 Billion USD | 13.7% |
| 2013 Q3 | 1.82 Billion USD | 6.05% |
| 2013 FY | 6.93 Billion USD | 25.66% |
| 2013 Q1 | 1.41 Billion USD | -0.2% |
| 2013 Q2 | 1.72 Billion USD | 21.79% |
| 2013 Q4 | 1.96 Billion USD | 7.55% |
| 2012 Q1 | 1.29 Billion USD | -2.62% |
| 2012 Q3 | 1.09 Billion USD | -22.74% |
| 2012 Q4 | 1.41 Billion USD | 29.17% |
| 2012 Q2 | 1.42 Billion USD | 9.98% |
| 2012 FY | 5.51 Billion USD | 9.27% |
| 2011 FY | 5.04 Billion USD | 7.04% |
| 2011 Q4 | 1.32 Billion USD | 1.28% |
| 2011 Q3 | 1.3 Billion USD | 8.38% |
| 2011 Q2 | 1.2 Billion USD | 0.44% |
| 2011 Q1 | 1.2 Billion USD | -1.29% |
| 2010 Q1 | 1.1 Billion USD | -1.61% |
| 2010 FY | 4.71 Billion USD | 7.75% |
| 2010 Q4 | 1.21 Billion USD | 3.68% |
| 2010 Q3 | 1.17 Billion USD | -3.04% |
| 2010 Q2 | 1.21 Billion USD | 9.36% |
| 2009 Q4 | 1.12 Billion USD | 0.58% |
| 2009 Q3 | 1.12 Billion USD | 2.49% |
| 2009 FY | 4.37 Billion USD | 6.83% |
| 2009 Q1 | 1.03 Billion USD | -3.03% |
| 2009 Q2 | 1.09 Billion USD | 5.48% |
| 2008 FY | 4.09 Billion USD | 29.19% |
| 2008 Q1 | 942.18 Million USD | 5.47% |
| 2008 Q2 | 993.44 Million USD | 5.44% |
| 2008 Q3 | 1.09 Billion USD | 10.02% |
| 2008 Q4 | 1.06 Billion USD | -2.2% |
| 2007 FY | 3.17 Billion USD | 69.41% |
| 2007 Q2 | 773.17 Million USD | 8.0% |
| 2007 Q3 | 789.23 Million USD | 2.08% |
| 2007 Q4 | 893.3 Million USD | 13.19% |
| 2007 Q1 | 715.91 Million USD | 798.29% |
| 2006 Q3 | 703.49 Million USD | 6.58% |
| 2006 Q4 | -102.52 Million USD | -114.57% |
| 2006 Q2 | 660.04 Million USD | 8.0% |
| 2006 Q1 | 611.17 Million USD | 903.88% |
| 2006 FY | 1.87 Billion USD | 9.25% |
| 2005 Q4 | -76.02 Million USD | -112.75% |
| 2005 FY | 1.71 Billion USD | 7.38% |
| 2005 Q2 | 605.63 Million USD | 3.03% |
| 2005 Q1 | 587.8 Million USD | 2202.07% |
| 2005 Q3 | 596.21 Million USD | -1.56% |
| 2004 Q3 | 543.27 Million USD | 0.84% |
| 2004 Q4 | -27.96 Million USD | -105.15% |
| 2004 FY | 1.59 Billion USD | 134.96% |
| 2004 Q1 | 541.74 Million USD | 275.35% |
| 2004 Q2 | 538.76 Million USD | -0.55% |
| 2003 Q1 | 320.69 Million USD | 6.04% |
| 2003 Q3 | 341.78 Million USD | 4.96% |
| 2003 Q4 | -308.94 Million USD | -190.39% |
| 2003 Q2 | 325.64 Million USD | 1.54% |
| 2003 FY | 679.18 Million USD | -40.86% |
| 2002 Q3 | 288.32 Million USD | 7.08% |
| 2002 Q4 | 302.43 Million USD | 4.89% |
| 2002 Q2 | 269.26 Million USD | -6.62% |
| 2002 Q1 | 288.34 Million USD | 2.81% |
| 2002 FY | 1.14 Billion USD | 10.06% |
| 2001 Q2 | 260.66 Million USD | 9.96% |
| 2001 Q3 | 265.19 Million USD | 1.74% |
| 2001 Q4 | 280.45 Million USD | 5.76% |
| 2001 FY | 1.04 Billion USD | 12.62% |
| 2001 Q1 | 237.04 Million USD | -3.38% |
| 2000 Q1 | 216.84 Million USD | -3.77% |
| 2000 Q3 | 233.75 Million USD | 1.41% |
| 2000 Q2 | 230.51 Million USD | 6.3% |
| 2000 Q4 | 245.33 Million USD | 4.95% |
| 2000 FY | 926.45 Million USD | 16.62% |
| 1999 Q1 | 171.7 Million USD | 1.97% |
| 1999 Q3 | 208.4 Million USD | 10.32% |
| 1999 Q4 | 225.33 Million USD | 8.13% |
| 1999 FY | 794.43 Million USD | 42.48% |
| 1999 Q2 | 188.9 Million USD | 10.02% |
| 1998 Q2 | 128.8 Million USD | 12.49% |
| 1998 Q4 | 168.38 Million USD | 15.41% |
| 1998 FY | 557.58 Million USD | 28.46% |
| 1998 Q1 | 114.5 Million USD | -21.65% |
| 1998 Q3 | 145.9 Million USD | 13.28% |
| 1997 Q3 | 100.6 Million USD | 8.87% |
| 1997 FY | 434.04 Million USD | 56.64% |
| 1997 Q1 | 94.8 Million USD | -9.53% |
| 1997 Q2 | 92.4 Million USD | -2.53% |
| 1997 Q4 | 146.14 Million USD | 45.27% |
| 1996 FY | 277.09 Million USD | 82.67% |
| 1996 Q4 | 104.79 Million USD | 8.25% |
| 1996 Q3 | 96.8 Million USD | 134.95% |
| 1996 Q2 | 41.2 Million USD | 19.77% |
| 1996 Q1 | 34.4 Million USD | -35.21% |
| 1995 Q3 | 33.9 Million USD | 3.67% |
| 1995 Q4 | 53.09 Million USD | 56.61% |
| 1995 FY | 151.69 Million USD | -2.98% |
| 1995 Q2 | 32.7 Million USD | 2.19% |
| 1995 Q1 | 32 Million USD | -25.48% |
| 1994 FY | 156.34 Million USD | 14.62% |
| 1994 Q1 | 41.2 Million USD | 17.05% |
| 1994 Q2 | 32.8 Million USD | -20.39% |
| 1994 Q3 | 31.8 Million USD | -3.05% |
| 1994 Q4 | 42.94 Million USD | 35.04% |
| 1993 FY | 136.4 Million USD | 10.27% |
| 1993 Q2 | 34.7 Million USD | 6.77% |
| 1993 Q1 | 32.5 Million USD | -36.89% |
| 1993 Q4 | 35.2 Million USD | 3.83% |
| 1993 Q3 | 33.9 Million USD | -2.31% |
| 1992 FY | 123.7 Million USD | 101.47% |
| 1992 Q3 | 37.9 Million USD | 109.39% |
| 1992 Q4 | 51.5 Million USD | 35.88% |
| 1992 Q2 | 18.1 Million USD | 12.42% |
| 1992 Q1 | 16.1 Million USD | 4.55% |
| 1991 FY | 61.4 Million USD | 22.55% |
| 1991 Q2 | 15.3 Million USD | -3.77% |
| 1991 Q4 | 15.4 Million USD | 4.05% |
| 1991 Q3 | 14.8 Million USD | -3.27% |
| 1991 Q1 | 15.9 Million USD | 15.22% |
| 1990 Q1 | 11.8 Million USD | 57.33% |
| 1990 Q4 | 13.8 Million USD | 10.4% |
| 1990 Q3 | 12.5 Million USD | 4.17% |
| 1990 Q2 | 12 Million USD | 1.69% |
| 1990 FY | 50.1 Million USD | 75.79% |
| 1989 Q2 | 6.9 Million USD | -14.81% |
| 1989 FY | 28.5 Million USD | 38.35% |
| 1989 Q1 | 8.1 Million USD | 44.64% |
| 1989 Q3 | 7 Million USD | 1.45% |
| 1989 Q4 | 7.5 Million USD | 7.14% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Imunon, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 147981.522% |
| uniQure N.V. | 15.84 Million USD | -61981.676% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -280917.143% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -31374.927% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -36568.531% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -2362.865% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -114627.633% |
| bluebird bio, Inc. | 29.49 Million USD | -33244.408% |
| Blueprint Medicines Corporation | 249.38 Million USD | -3844.021% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -46807.669% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | -4134.299% |
| Editas Medicine, Inc. | 78.12 Million USD | -12489.89% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -8354.622% |
| Geron Corporation | 237 Thousand USD | -4149942.194% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -7641.885% |
| Illumina, Inc. | 4.5 Billion USD | -118.375% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -827116.148% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 34.359% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -159.63% |
| Myriad Genetics, Inc. | 678.4 Million USD | -1349.823% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -421.202% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -691.065% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -1518.973% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 93.339% |
| Waters Corporation | 2.95 Billion USD | -232.687% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 0.34% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 77.05% |
| Nektar Therapeutics | 90.12 Million USD | -10813.65% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | -111.264% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -306.56% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -5481.052% |
| Evolus, Inc. | 202.08 Million USD | -4767.061% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 25.018% |
| FibroGen, Inc. | 147.75 Million USD | -6556.83% |
| Agilent Technologies, Inc. | 6.83 Billion USD | -43.943% |
| OPKO Health, Inc. | 863.49 Million USD | -1039.045% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -437.967% |
| Exelixis, Inc. | 1.83 Billion USD | -437.403% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -27013.99% |
| Zoetis Inc. | 8.54 Billion USD | -15.117% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -3534.738% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -1148.732% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -1938.995% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -1086.08% |
| Insmed Incorporated | 305.2 Million USD | -3122.589% |
| TG Therapeutics, Inc. | 233.66 Million USD | -4109.328% |
| Incyte Corporation | 3.69 Billion USD | -166.14% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -837.349% |